Use: Labeled indications
- Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness
Full indications and usage US FDA label
Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness
Dosing: Adult
Dosage and administration (US label) US FDA label
Directions do not take more than directed to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity to prevent or treat motion sickness, see below: adults and children 12 years and over ■ take 1 to 2 tablets every 4-6 hours ■ do not take more than 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years ■ give 1/2 to 1 tablet every 6-8 hours ■ do not give more than 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years ■ give 1/2 tablet every 6-8 hours ■ do not give more than 1 1/2 tablets in 24 hours, or as directed by a doctor
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Tablet: 25 mg, 50 mg
- Syrup: 12.5 mg/5 mL
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Dimenhydrinate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
NedzadinDimenhydrinate | 12.5 mg/5 mL SyrupAmber Glass Bottle x 60 mL | Rx | Drugmakers Laboratories, IncPhilippines | — | DRP-5551 | Jan 27, 2030 | |
NedzadinDimenhydrinate | 25 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5724 | Apr 29, 2029 | |
NoneDimenhydrinate | 50 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Drugmakers Laboratories IncPhilippines | — | DRP-5827 | May 16, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
Warnings Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.
When using this product marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness avoid alcoholic beverages use caution when driving a motor vehicle or operating machinery If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Motion Sickness Relief · Amerisource Bergen [US FDA-approved label, version 13, September 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4077301-db6c-473d-beb3-232d7134a13a
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .